share_log

Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering

Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering

Tonix Pharmicals宣佈註冊直接發行的定價爲440萬美元
Tonix Pharmaceuticals ·  03/28 12:00

Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering

Tonix Pharmicals宣佈註冊直接發行的定價爲440萬美元

March 28, 2024 9:32am EDT Download as PDF

2024 年 3 月 28 日美國東部時間上午 9:32 以 PDF 格式下載

CHATHAM, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a biopharmaceutical company, today announced it has entered into a securities purchase agreement with existing healthcare focused institutional investors of the Company for the purchase and sale of 14,666,666 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 14,666,666 shares of common stock in a registered direct offering at a combined offering price of $0.30 per share and accompanying warrant. The warrants have an exercise price of $0.33 per share, will be exercisable commencing six months from the date of issuance and will expire five and one-half years following the date of issuance. The closing of the offering is expected to take place on or about April 1, 2024, subject to the satisfaction of customary closing conditions.

新澤西州查塔姆,2024年3月28日(GLOBE NEWSWIRE)——生物製藥公司Tonix Pharmicals Holding Corp.(納斯達克股票代碼:TNXP)(“Tonix” 或 “公司”)今天宣佈,它已與公司現有的以醫療保健爲重點的機構投資者簽訂證券購買協議,購買和出售14,666股普通股(或普通股等價物)取而代之)以及以每股0.30美元的合併發行價格在註冊直接發行中購買最多14,666,666股普通股的認股權證股份和附帶的認股權證。認股權證的行使價爲每股0.33美元,自發行之日起六個月內可行使,並將自發行之日起五年半到期。此次發行預計將於2024年4月1日左右結束,但須滿足慣例成交條件。

The gross proceeds of the offering will be approximately $4.4 million before deducting placement agent fees and other estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes, as well as for the satisfaction of a portion of the Company's debt.

在扣除配售代理費和公司應付的其他預計發行費用之前,本次發行的總收益約爲440萬美元。公司打算將本次發行的淨收益用於營運資金和一般公司用途,並用於償還公司的部分債務。

A.G.P./Alliance Global Partners is acting as sole placement agent for the offering.

A.G.P./Alliance Global Partners是本次發行的唯一配售代理。

In connection with this offering, the Company has also agreed that certain existing warrants issued in August 2023 to purchase up to an aggregate of 6,950,000 shares at an exercise price of $1.00 per share and a termination date of August 2028, will be amended, so that the amended warrants will have a reduced exercise price of $0.33 per share and a termination date of April 2029. The company has further agreed that certain existing warrants issued in October 2023 to purchase up to an aggregate of approximately 17,800,000 shares with an exercise price of $0.50 per share and termination dates ranging from October 2024 to October 2028, will be amended, so that the amended warrants will have a reduced exercise price of $0.33 per share and a termination date of April 2025 and April 2029, respectively. The company has further agreed that certain existing Series C and Series D warrants issued in December 2023 to purchase up to an aggregate of 69,647,856 shares with respective exercise prices ranging from $0.55 to $0.85 per share and termination dates ranging from December 2025 to December 2028, will be amended, so that the amended warrants will have a reduced exercise price of $0.33 per share and a termination date equal to the earlier of April 2026 and 10 trading days following notice by the Company to the warrant holder of the Company's public announcement of the U.S. Food and Drug Administration's acknowledgement and acceptance of the Company's new drug application relating to TNX-102 SL in patients with Fibromyalgia for the Series C warrants and April 2029 for the Series D warrants. All of the amendments to the August 2023, October 2023 and December 2023 warrants are subject to shareholder approval, if shareholder approval is not received on or before the six-month anniversary of the closing of this offering, such existing warrants will have an exercise price equal to the Nasdaq minimum price on the six-month anniversary of the closing of this offering. The other terms of such warrants will remain unchanged.

在本次發行中,公司還同意對2023年8月發行的某些現有認股權證進行修改,這些認股權證的行使價爲每股1.00美元,總共購買6,95萬股股票,終止日期爲2028年8月,因此修訂後的認股權證的行使價將降低爲每股0.33美元,終止日期爲2029年4月。該公司進一步同意,將修訂2023年10月發行的某些現有認股權證,總共購買約17,800,000股股票,行使價爲每股0.50美元,終止日期爲2024年10月至2028年10月,因此修訂後的認股權證的行使價將降低爲每股0.33美元,終止日期分別爲2025年4月和2029年4月。該公司還同意,將對2023年12月發行的某些現有C系列和D系列認股權證進行修改,總共購買69,647,856股股票,各自的行使價在每股0.55美元至0.85美元之間,終止日期爲2025年12月至2028年12月,因此修訂後的認股權證的行使價將降低爲每股0.33美元,終止日期等於較早的2026年4月和之後的10個交易日公司向認股權證持有人發出的關於本公司公告的通知美國食品藥品監督管理局承認並接受該公司針對纖維肌痛患者的 TNX-102 SL 的 C 系列認股權證和 2029 年 4 月 D 系列認股權證的新藥申請。2023年8月、2023年10月和2023年12月認股權證的所有修正均須經股東批准,如果在本次發行結束六個月週年紀念日當天或之前未獲得股東批准,則此類現有認股權證的行使價將等於本次發行結束六個月週年之內納斯達克的最低價格。此類認股權證的其他條款將保持不變。

This offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-266982) previously filed with the U.S. Securities and Exchange Commission (the "SEC"). A prospectus supplement describing the terms of the proposed Offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov. Electronic copies of the prospectus supplement may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@allianceg.com.

本次發行是根據先前向美國證券交易委員會(“SEC”)提交的S-3表格(文件編號333-266982)上的有效貨架註冊聲明進行的。描述擬議發行條款的招股說明書補充文件將提交給美國證券交易委員會,並將在美國證券交易委員會的網站上公佈,網址爲 http://www.sec.gov。招股說明書補充文件的電子副本(如果有)可向位於紐約麥迪遜大道590號28樓的A.G.P/Alliance Global Partners索取,紐約10022,或致電(212)624-2060或發送電子郵件至 prospectus@allianceg.com。

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

本新聞稿不構成出售要約或徵求購買這些證券的要約,在根據任何此類州或其他司法管轄區的證券法進行註冊或獲得資格認證之前,在任何州或其他司法管轄區出售此類證券是非法的,也不得在任何州或其他司法管轄區出售這些證券。

Tonix Pharmaceuticals Holding Corp.*

託尼克斯製藥控股公司*

Tonix is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. Tonix's priority is to submit a New Drug Application (NDA) to the FDA in the second half of 2024 for Tonmya, a product candidate for which two positive Phase 3 studies have been completed for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction as well as fibromyalgia-type Long COVID. Tonix's CNS portfolio includes TNX-1300 (cocaine esterase) a biologic designed to treat cocaine intoxication with Breakthrough Therapy designation. Tonix's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease. Tonix Medicines, our commercial subsidiary, markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults.

Tonix是一家生物製藥公司,專注於開發、許可和商業化治療和預防人類疾病並減輕痛苦的療法。Tonix的開發產品組合側重於中樞神經系統(CNS)疾病。Tonix的首要任務是在2024年下半年向美國食品藥品管理局提交Tonmya的新藥申請(NDA)。Tonmya的候選產品已經完成了兩項針對纖維肌痛管理的陽性3期研究。TNX-102 SL也在開發中,用於治療急性應激反應以及纖維肌痛型的長冠狀病毒。Tonix 的中樞神經系統產品組合包括 TNX-1300(可卡因酯酶),這是一種旨在治療可卡因中毒的生物製劑,被命名爲 “突破性療法”。Tonix 的免疫學開發產品組合包括用於解決器官移植排斥反應、自身免疫和癌症的生物製劑,包括 TNX-1500,這是一種靶向 CD40 配體(CD40L 或 CD154)的人源化單克隆抗體,正在開發用於預防同種異體移植排斥反應和治療自身免疫性疾病。Tonix還在罕見病和傳染病領域開發候選產品。我們的商業子公司Tonix Medicines銷售3毫克的Zembrace SymTouch(舒馬曲坦注射液)和10毫克的Tosymra(舒馬曲坦鼻腔噴霧劑),用於治療成人有或沒有先兆的急性偏頭痛。

*Tonix's product development candidates are investigational new drugs or biologics and have not been approved for any indication. Tonmya is conditionally accepted by the U.S. Food and Drug Administration as the tradename for TNX-102 SL for the management of fibromyalgia.

*Tonix的候選產品是研究中的新藥或生物製劑,尚未獲得任何適應症的批准。美國食品藥品監督管理局有條件地接受 Tonmya 作爲 TNX-102 SL 的商品名,用於治療纖維肌痛。

Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners.

Zembrace SymTouch 和 Tosymra 是 Tonix Medicines 的註冊商標。所有其他商標均爲其各自所有者的財產。

This press release and further information about Tonix can be found at www.tonixpharma.com.

本新聞稿和有關 Tonix 的更多信息可在www.tonixpharma.com上找到。

Forward Looking Statements

前瞻性陳述

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 including those relating to the completion of the offering, the satisfaction of customary closing conditions, the intended use of proceeds from the offering and other statement that are predictive in nature. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," and "intend," among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the Securities and Exchange Commission (the "SEC") on March 13, 2023, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

根據1995年《私人證券訴訟改革法》的定義,本新聞稿中的某些聲明具有前瞻性,包括與發行完成、慣例成交條件的滿足、發行所得收益的預期用途以及其他具有預測性的聲明有關的聲明。這些陳述可以通過使用前瞻性詞語來識別,例如 “預期”、“相信”、“預測”、“估計”、“預期” 和 “打算” 等。這些前瞻性陳述基於Tonix當前的預期,實際業績可能存在重大差異。有許多因素可能導致實際事件與此類前瞻性陳述所示事件存在重大差異。這些因素包括但不限於與未能獲得美國食品藥品管理局許可或批准以及不遵守美國食品藥品管理局法規相關的風險;與未能成功銷售我們的任何產品相關的風險;與候選產品臨床開發的時間和進展相關的風險;我們對額外融資的需求;專利保護和訴訟的不確定性;政府或第三方付款人補償的不確定性;研發工作有限以及對第三方的嚴重依賴;以及大量的依賴競爭。與任何正在開發的藥物一樣,新產品的開發、監管批准和商業化也存在重大風險。Tonix沒有義務更新或修改任何前瞻性陳述。投資者應閱讀2023年3月13日向美國證券交易委員會(“SEC”)提交的截至2022年12月31日年度的10-K表年度報告以及該報告當天或之後向美國證券交易委員會提交的定期報告中列出的風險因素。Tonix的所有前瞻性陳述均受所有這些風險因素和其他警示性陳述的明確限制。此處提供的信息僅反映截至發佈之日的信息。

Investor Contact
Jessica Morris
Tonix Pharmaceuticals
investor.relations@tonixpharma.com
(862) 904-8182

投資者聯繫人
傑西卡莫里
託尼克斯製藥
investor.relations@tonixpharma.com
(862) 904-8182

Peter Vozzo
ICR Westwicke
peter.vozzo@westwicke.com
(443) 213-0505

彼得·沃佐
ICR Westwicke
peter.vozzo@westwicke.com
(443) 213-0505

Media Contact
Ben Shannon
ICR Westwicke
ben.shannon@westwicke.com
(919) 360-3039

媒體聯繫人
本·香農
ICR Westwicke
ben.shannon@westwicke.com
(919) 360-3039


Primary Logo

Source: Tonix Pharmaceuticals Holding Corp.
來源:Tonix 製藥控股公司

Released March 28, 2024

2024 年 3 月 28 日發佈

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論